Conservative Treatment of Rectosigmoid Endometriosis Monitored by Transvaginal Ultrasound
This trial is active, not recruiting.
|Sponsor||University of Aarhus|
|Start date||October 2014|
|End date||February 2017|
|Trial size||100 participants|
|Trial identifier||NCT02100345, 1-10-72-196-13, Bowel Endometriosis|
Background: Endometriosis is a disease affecting 8-15 % of fertile women and is a cause of abdominal pain and suffering during women's menstrual periods. A subgroup of patients with DIE has an infiltration into the rectosigmoid bowel wall (4-37%). Knowledge of the growth pattern of rectosigmoid lesions related to subjective symptoms is mandatory in order to assess the need for follow-up with transvaginal ultrasound during medical treatment.
Symptoms will follow growth of rectosigmoid endometriosis.
Material and methods:
Two different cohorts of women, based on time of diagnosis of rectosigmoid endometriosis and treatment with hormonal intrauterine device or continuous oral contraceptives will receive a questionnaire and a transvaginal ultrasound scan (measuring size and volume) at inclusion, (6) and 12 months later.
Patients treated conservatively may be followed by questionnaires, thereby reducing the need for time consuming clinical controls.
time frame: 29 months
Female participants from 18 years up to 80 years old.
Inclusion Criteria: - Medically treated bowel endometriosis Exclusion Criteria: - Age below 18 years - Bowel resection of any kind - Cancer
|Official title||Conservative Treatment of Rectosigmoid Endometriosis Monitored by Transvaginal Ultrasound|
Call for more information